Myriad Publications  |   Documents and Forms  |   Registries

Oncology

Myriad myRisk® Hereditary Cancer

A scientific advancement revolutionizing hereditary cancer testing

Blending both genetic test status AND personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. Additionally, Myriad myRisk provides a summary of medical society guidelines to help you optimize your patients’ medical management. Be confident you know your patients' cancer risks and appropriate follow-up management with Myriad myRisk Hereditary Cancer.

Who to Test

Consistent consideration of cancer family history and genetic test status will dramatically change your medical management recommendations for all patient types. Our Patient ID Card can help you identify patients with red flags. There are two essential steps to identify your patients for Hereditary Cancer Risk in order to optimize your medical management:

Screen

Cancer family history questionnaire

Ask each patient to fill one out to capture 3 degrees of cancer history for both maternal and paternal family members. Emphasizing to your patients the importance of capturing a thorough family history will allow you to better evaluate their hereditary cancer risk and appropriateness for testing.

Evaluate

Review your patient's Cancer Family History using consistent red flags to determine if your patient is at increased risk for hereditary cancers.

Multiple

A combination of cancers on the same side of the family
  • 2 or more: breast / ovarian / prostate / pancreatic cancer
  • 2 or more: colorectal / endometrial / ovarian / gastric / pancreatic / other cancers (i.e., ureter/renal pelvis, biliary tract, small bowel, brain, sebaceous adenomas)
  • 2 or more: melanoma / pancreatic cancer

Young

Any one of the following cancers at age 50 or younger
  • Breast cancer
  • Colorectal cancer
  • Endometrial cancer

Rare

Any one of these rare presentations at any age
  • Ovarian cancer
  • Breast: male breast cancer or triple negative breast cancer
  • Colorectal cancer with abnormal MSI/IHC, MSI associated histology††
  • Endometrial cancer with abnormal MSI/IHC
  • 10 or more gastrointestinal polyps*
Certain ancestries may have greater risk for hereditary cancer syndromes (e.g., Ashkenazi Jewish ancestry)

Sequencing and Data Review

Variant Interpretation

Test Optimization and Lab Accuracy

Myriad used our experience with over a million patients tested to further optimize Myriad myRisk® testing with next generation sequencing (NGS). NGS allows for rapid sequencing of multiple genes concurrently. In the largest validation study of its kind, Myriad estimated analytical sensitivity of greater than 99.92% with 100% concordance on NGS/Sanger parallel sequencing in all genes in the Myriad myRisk panel and 100% concordance on large rearrangement validation.

Myriad myRisk's gold standard NGS technology serves as only one part of the many steps that Myriad pursues to ensure the highest quality and sensitivity for every sample that is submitted. The following cycle shows the extensive laboratory process from DNA extraction and sequencing to laboratory director approved reports.

Test Optimization and Lab Accuracy

Waiting for results can increase patient anxiety and delay your medical decisions. Myriad believes optimal patient care should include a rapid turnaround-time for test results. Myriad myRisk provides an average turnaround-time of 2-3 weeks.



Over 20 years, Myriad has conducted over a million tests for hereditary cancer.

Myriad is the unquestioned industry leader in variant classification and reclassification. myVision™ is the most advanced program in the industry overseeing the classification and reclassification of uncertain variants and is part of Myriad’s commitment to patients and their families that lasts a lifetime.

Variation in human genes is enormous, with new genetic changes discovered every day. That’s why variants of uncertain significance (VUS) are expected in genetic testing. For a patient who undergoes genetic testing, a VUS result can be confusing; for healthcare providers, counseling these patients can be a challenge:

  • A VUS result raises questions yet offers no clear answers for patients, families, or healthcare providers
  • Positive results trigger cancer risk management plans
  • Negative results help avoid unnecessary screenings and surgery

The resulting analysis and interpretation of the variant database support the Myriad commitment to reduce VUS in genetic test results and ensure:

  • Accurate, clinically significant results from every Myriad test performed
  • Reduced uncertainty for patients and families
  • Confidence for providers counseling their patients

Provider Support

  • Billing Assistance
  • Updated Reports
  • Updated Reports
  • Medical Specialists
  • Customer Service
  • Electronic Reporting
  • Field Genetic Experts
  • Specialized Sales Force
  • Protocol/Process Expertise

Financial Support

  • Myriad Promise™
  • Myriad Financial Assistance Program (MFAP)

Patient Support

  • Education
  • Quality Result
  • Financial Support
  • Lifetime Clinical Support
  • Broad Insurance Coverage
  • Gold Standard Variant
  • Classification
  • mySupport360

WITH more than 20 years of experience, 1 million patients’ lives affected WITH A RESULT, AND over 65,000 testing providers, MYRIAD IS THE WORLD LEADER IN HEREDITARY CENTER TESTING.